Table 4.
Unconditional Logistic Regression Analyses of Selected Hormones and Male Breast Cancer According to Age and BMI
| Variable | Age at Diagnosis |
BMI |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 67 Years |
≥ 67 Years |
< 25.07 |
≥ 25.07 |
|||||||||
| No. of Exposed Cases | OR* | 95% CI | No. of Exposed Cases | OR* | 95% CI | No. of Exposed Cases | OR† | 95% CI | No. of Exposed Cases | OR† | 95% CI | |
| Testosterone, nmol/L | ||||||||||||
| < 10.02 | 7 | 1.00 | Referent | 12 | 1.00 | Referent | 7 | 1.00 | Referent | 12 | 1.00 | Referent |
| 10.02 to < 13.07 | 12 | 1.45 | 0.48 to 4.39 | 7 | 0.65 | 0.21 to 2.02 | 9 | 1.31 | 0.40 to 4.29 | 10 | 0.83 | 0.30 to 2.32 |
| 13.07 to < 16.40 | 15 | 1.82 | 0.63 to 5.28 | 11 | 1.12 | 0.38 to 3.29 | 13 | 1.64 | 0.54 to 4.98 | 13 | 1.39 | 0.51 to 3.82 |
| ≥ 16.40 | 16 | 2.08 | 0.71 to 6.11 | 12 | 1.10 | 0.38 to 3.21 | 16 | 2.07 | 0.69 to 6.24 | 12 | 1.26 | 0.46 to 3.49 |
| Continuous | 50 | 1.32 | 0.57 to 3.02 | 42 | 0.98 | 0.39 to 2.44 | 45 | 1.41 | 0.64 to 3.13 | 47 | 1.01 | 0.39 to 2.64 |
| Estradiol, pmol/L | ||||||||||||
| < 50.69 | 7 | 1.00 | Referent | 6 | 1.00 | Referent | 9 | 1.00 | Referent | 4 | 1.00 | Referent |
| 50.69 to < 64.09 | 11 | 2.06 | 0.70 to 6.11 | 6 | 0.91 | 0.24 to 3.45 | 10 | 1.65 | 0.57 to 4.77 | 7 | 1.51 | 0.37 to 6.12 |
| 64.09 to < 84.82 | 19 | 3.56 | 1.27 to 9.94 | 14 | 2.43 | 0.72 to 8.16 | 13 | 2.53 | 0.89 to 7.17 | 20 | 3.81 | 1.94 to 13.86 |
| ≥ 84.82 | 13 | 3.17 | 1.06 to 9.42 | 16 | 1.70 | 0.49 to 5.91 | 13 | 2.20 | 0.74 to 6.57 | 16 | 3.47 | 0.92 to 13.11 |
| Continuous | 50 | 3.08 | 1.21 to 7.84 | 42 | 1.21 | 0.53 to 2.75 | 45 | 1.66 | 0.75 to 3.69 | 47 | 2.32 | 0.90 to 5.96 |
| Estradiol to sum of ADT-G, 3α-diol-3G, 3α-diol-17G, and DHT ratio | ||||||||||||
| < 0.0005 | 12 | 1.00 | Referent | 3 | 1.00 | Referent | 8 | 1.00 | Referent | 7 | 1.00 | Referent |
| 0.0005 to < 0.0007 | 11 | 0.94 | 0.36 to 2.47 | 7 | 1.46 | 0.29 to 7.36 | 10 | 1.11 | 0.37 to 3.34 | 8 | 1.49 | 0.44 to 5.10 |
| 0.0007 to < 0.0010 | 13 | 1.38 | 0.52 to 3.66 | 10 | 1.35 | 0.29 to 6.32 | 9 | 1.54 | 0.46 to 5.18 | 14 | 1.45 | 0.47 to 4.48 |
| ≥ 0.0010 | 12 | 2.71 | 0.97 to 7.61 | 22 | 1.94 | 0.40 to 9.30 | 16 | 2.06 | 0.63 to 6.74 | 18 | 2.89 | 0.81 to 10.24 |
| Continuous | 48 | 1.65 | 0.88 to 3.09 | 42 | 1.01 | 0.65 to 1.56 | 43 | 1.37 | 0.74 to 2.57 | 47 | 1.10 | 0.71 to 1.69 |
Abbreviations: 3α-diol-3G, 3-androstanediol-3 glucuronide; 3α-diol-17G, 3-androstanediol-17 glucuronide; ADT-G, androsterone glucuronide; BMI, body mass index; DHT, dihydrotestosterone; OR, odds ratio.
*
Adjusted for race, date at blood draw, age at blood draw, and BMI (continuous). Continuous sex steroid hormone values were standardized to half of difference between 75th and 25th centiles of distribution before correlative analysis.
†
Adjusted for race, date at blood draw, and age at blood draw.